Oliver Hatley

Animal versus human oral drug bioavailability: Do they correlate?

Helen Musther, Andrés Olivares‐Morales, Oliver Hatley et al. · European Journal of Pharmaceutical Sciences · 2013 · 202 citations · Full text

Oral Bioavailability, Preclinical Drug Evaluation, Bioavailability Calculations +13

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

Lisa M. Almond, Sophie Mukadam, I. Gardner et al. · Drug Metabolism and Disposition · 2016 · 99 citations · Full text

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

Aki T. Heikkinen, Arno Friedlein, Mariette Matondo et al. · Pharmaceutical Research · 2014 · 55 citations

Ugt Enzymes, Proteomic Technology, Protein Function +9

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport

Sonia Pahwa, Khondoker Alam, Alexandra Crowe et al. · Journal of Pharmaceutical Sciences · 2017 · 52 citations · Full text

Signal Transduction, Medicine, Receptor Tyrosine Kinase +5

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

Andrés Olivares‐Morales, Oliver Hatley, David B. Turner et al. · Pharmaceutical Research · 2013 · 44 citations · Full text